ArticlesSerotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study
Introduction
Since 2010, the seven-valent pneumococcal conjugate vaccine (PCV7) has been replaced in many countries by higher valency vaccines containing ten (PCV10, GlaxoSmithKline, Brentford, UK) or 13 (PCV13, Pfizer, New York, NY, USA) serotypes. This change in vaccine became necessary as a result of the change in serotypes causing invasive pneumococcal disease, partly driven by the use of PCV7. The high effectiveness of PCV7 at reducing vaccine-type invasive pneumococcal disease1 has been partly offset by an increase in invasive pneumococcal disease caused by non-vaccine serotypes.2, 3 The serotypes that emerged as major causes of invasive pneumococcal disease after the widespread use of PCV7 include many of the additional serotypes in PCV10 and PCV13.
Assessment of vaccine effectiveness for the newer, extended-valency PCVs is of particular interest because, unlike PCV7, PCV10, and PCV13 were licensed on the basis of immunogenicity data alone. Head-to-head studies of PCV7 and the new vaccines with immunogenicity endpoints were deemed acceptable for licensing the new conjugates,4 largely because of the existence of a correlate of protection for PCV7. An anticapsular polysaccharide antibody concentration of 0·35 μg/mL measured by ELISA aggregated across all the seven serotypes in PCV7 is regarded as predictive of protection against invasive pneumococcal disease.5 This correlate was derived from three randomised trials of PCV7 or an experimental nine-valent conjugate (Wyeth, Collegeville, PA, USA) done in California, USA,6 in an Indigenous American population,7 and in South Africa,8 by correlation of post-primary IgG concentrations aggregated across the three studies with aggregate efficacy against invasive pneumococcal disease.5
Individual serotype-specific correlates could not be derived from the efficacy trials because even the largest PCV7 trial showed significant serotype-specific efficacy for only three of the seven serotypes, with wide CIs because of small numbers of cases of invasive pneumococcal disease.9 Researchers therefore derived an aggregate estimate, although serotype-specific differences in the amount of antibody needed to protect against invasive pneumococcal disease and otitis media are now recognised.10, 11 Pooled data from the heterogeneous populations investigated in the efficacy trials6, 7, 8 were used to narrow the confidence limits around the point estimate of efficacy, despite different levels of protection seen in these three populations. With effectiveness estimates for the additional serotypes in the extended-valency conjugates now available, the possibility exists to derive serotype-specific correlates of protection. More precise estimates will both aid decision making relevant to vaccine schedules and inform the licensure of next-generation extended-valency conjugates.
PCV13 replaced PCV7 in the UK on April 1, 2010. For both vaccines, a 2 + 1 schedule was used (at 2, 4, and 12 months). We previously reported on the effectiveness of PCV13 against vaccine-type invasive pneumococcal disease in the first 15 months after introduction in a case-control (indirect cohort) study.12 Here, we extend the estimates of effectiveness to 3·5 years after introduction. Additionally, using data from immunogenicity studies of PCV13 and PCV7 in infants in the UK and previously published data for the effectiveness of PCV7,13 we aimed to derive individual serotype-specific estimates of correlates of protection for the vaccine serotypes and to calculate the first serotype-specific functional correlates of protection based on opsonophagocytic killing.
Section snippets
Setting
We did a postlicensure indirect cohort study to investigate the serotype-specific effectiveness and correlates of protection for PCV13. We used cases of invasive pneumococcal disease (diagnosed in infants by culture of Streptococcus pneumoniae from a normally sterile site or by DNA detection in pleural fluid or cerebrospinal fluid) for which a serotype was identified. Cases were reported during a sufficiently long surveillance period (3·5 years and about 700 cases) to produce serotype-specific
Results
Of 716 serotyped cases of invasive pneumococcal disease, eight were assigned a serogroup only (serogroup 7) and were therefore excluded, and two other individuals had an unknown vaccination status. The remaining 706 cases included 30 PCV7 serotypes, 292 with the additional six PCV13 serotypes or 6C, and 414 with non-PCV13 serotypes. The serotype distribution varied by age, because of vaccine effects and possible natural differences in serotype distribution by age (table 1, appendix p 1). As
Discussion
The findings of our postlicensure indirect cohort study of the use of PCV13 over 3·5 years in England, Wales, and Northern Ireland show generally good vaccine effectiveness for four of the six new serotypes in PCV13 and high vaccine effectiveness against the PCV7 serotypes (panel). Of particular importance is evidence of significant protection against serotypes 7F and 19A, which have been major causes of replacement disease,2, 3 and protection against serotype 1, which is an important cause of
References (26)
- et al.
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
Lancet
(2006) - et al.
Serotype replacement in disease after pneumococcal vaccination
Lancet
(2011) - et al.
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
Lancet Infect Dis
(2011) - et al.
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants
Vaccine
(2003) - et al.
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial
Lancet
(2003) - et al.
Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
Vaccine
(2011) - et al.
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies
Vaccine
(2007) - et al.
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial
Lancet
(2005) - et al.
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study
Lancet
(2006) - et al.
WHO/Health Canada meeting on regulatory considerations for evaluation and licensing of new meningococcal Group B vaccines, Ottawa, Canada, 3–4 October 2011
Biologicals
(2012)
Recommendations for the production and control of pneumococcal conjugate vaccines. Technical Report Series 927
Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom
Pediatr Infect Dis J
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection
N Engl J Med
Cited by (397)
Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial
2023, Clinical Microbiology and Infection